Preclinical study demonstrates that scAAV-delivered NeuroD1 gene therapy reprograms glioblastoma cells into a neuronal-like state, highlighting a targeted strategy to curb aggressive tumor invasion.
The poor prognosis of glioblastoma patients stems from glioblastoma’s characteristic behavior of rapid invasive growth, an immunologically cold microenvironment, tumor heterogeneity, and a strong tendency to recur, with a dismal median survival of 12–18 months.1 Among the many research strategies, which are being deployed to dismantle the aggressiveness of glioblastoma at pre-clinical stage is the potential to reprogram this glial tumor to neuronal-like state, which reduces its growth potential and subsequent invasive behavior while limiting off-target effects on neighboring tissue.
No takes yet. Share an insight, caveat, or question.
Mazzetti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: